FDA 483 - Novartis Pharmaceuticals Corporation - August 05, 2014
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Novartis Pharmaceuticals Corp. in East Hanover, NJ, identified significant issues related to clinical trial oversight. The firm failed to promptly submit an IND safety report to the FDA and did not inform participating investigators in a timely manner regarding a suspected adverse reaction. Additionally, the inspection revealed a failure to ensure proper monitoring of the study, including missing monitoring visit reports and infrequent monitoring visits.
ID · 7b7960f8-08c8-49f2-a0bc-275ee2905eaa